Related Experiment Video
Updated: May 24, 2026
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
A double-blind study on clonazepam in patients with burning mouth syndrome
Siegfried M Heckmann1, Elena Kirchner, Miriam Grushka
1School of Dental Medicine, University of Erlangen-Nuremberg, Erlangen, Germany.
Objectives/Hypothesis:
In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results. The aim of the present randomized clinical trial was to determine the efficacy of clonazepam, a GABA agonist designed as an antiepileptic drug that exerts the typical effects of benzodiazepines.
Study Design:
Randomized clinical trial.
Methods:
Twenty patients with idiopathic BMS were carefully selected. Clonazepam (0.5 mg/day, n = 10) or placebo (lactose, n = 10) were randomly assigned to the patients.
Results:
Patients on clonazepam significantly improved in pain ratings (P < .001). These changes were less pronounced in the placebo group (P < .11). No significant changes were observed in a mood scale (P = .56) or for depression scores (P = .56). Taste test and salivary flow increased over sessions, but were not different between groups (P = .83 and P = .06, respectively).
Conclusions:
Clonazepam appears to have a positive effect on pain in BMS patients.
Related Concept Videos
02:07Blind Procedures
01:11Blinding
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...